GTx is a dedicated to developing novel targeted hormonal therapies. At GTx, there is a focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. GTx develops selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy. To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, GTx has a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.